Depending on the amount swallowed, gastric lavage is recommended. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvZHltaXN0YS1hemVsYXN0aW5lLWZsdXRpY2Fzb25lLWludHJhbmFzYWwtOTk5NzQ1 If you log out, you will be required to enter your username and password the next time you visit.

Infections of the nasal airways should be treated with antibacterial or antimycotical therapy, but do not constitute a specific contraindication to treatment with Dymista Nasal Spray.Dymista contains benzalkonium chloride. These findings are not likely to be relevant for humans given recommended nasal doses which results in minimal systemic exposure.

Therefore, drug displacement reactions are unlikely.Fluticasone propionate is cleared rapidly from the systemic circulation, principally by hepatic metabolism to an inactive carboxylic acid metabolite, by the cytochrome P450 enzyme CYP3A4. This may result in a higher frequency of systemic adverse events. There are no or limited amount of data from the use of azelastine hydrochloride and fluticasone propionate in pregnant women. It significantly improved ocular symptoms (comprising itching, tearing/watering and redness of the eyes) and the patients' disease-related quality of life (Rhinoconjunctivitis Quality of Life Questionnaire – RQLQ) in all 4 studies.In comparison to a marketed fluticasone propionate nasal spray substantial symptom improvement (50% reduction in nasal symptoms severity) was achieved significantly earlier (3 days and more) with Dymista Nasal Spray. Dymista Nasal Spray was equivalent to a marketed azelastine nasal spray with respect to azelastine systemic exposure. This website also contains material copyrighted by 3rd parties.

The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side effects. and formulary information changes. There is no known antidote.Pharmacotherapeutic group: Decongestants and other nasal preparations for topical use, corticosteroids/ fluticasone, combinations, ATC code: R01AD58.Dymista Nasal Spray contains azelastine hydrochloride and fluticasone propionate, which have different modes of action and show synergistic effects in terms of improvement of allergic rhinitis and rhino-conjunctivitis symptoms.Fluticasone propionate is a synthetic trifluorinated corticosteroid that possesses a very high affinity for the glucocorticoid receptor and has a potent anti-inflammatory action, e.g. Azelastine demonstrated no genotoxic potential in a battery of in vitro and in vivo tests, nor any carcinogenic potential in rats or mice.

Prior to first use Dymista Nasal Spray must be primed by pressing down and releasing the pump 6 times. Diseases & Conditions provider for the most current information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information. This information is intended for use by health professionalsEach g of suspension contains 1000 micrograms azelastine hydrochloride and 365 micrograms fluticasone propionate. Dymista Nasal Spray should be used during lactation only if the potential benefit justifies the potential risk to the newborns/infant (see section 5.3).Dymista Nasal Spray has minor influence on the ability to drive and use machines.In isolated cases fatigue, weariness, exhaustion, dizziness or weakness that may also be caused by the disease itself, may occur when using Dymista Nasal Spray. Prime the bottle before initial use by releasing 6 sprays or more until a fine mist spraysReprime the bottle if unused for >14 days by spraying once or more until fine mist appearsPrime the bottle before initial use by releasing 6 sprays or more until a fine mist spraysReprime the bottle if unused for >14 days by spraying once or more until fine mist appearsSeasonal allergic rhinitis: Clinical trials did not include sufficient numbers of patients older than 65 years to determine whether they respond differently from younger patientsInitiate at low end of dosing range and exercise cautionNasal effects (eg, nasal ulceration, nasal septal perforation)Hypothalamic-pituitary-adrenal (HPA) axis suppressionAvoid spraying directly into eyes; if drug is sprayed into eyes, flush with water for a minimum of 10 minutesMay cause somnolence; avoid operating heavy machinery or engaging in tasks that require mental alertness and coordinationDo not use with history of recent nasal ulcers, nasal surgery, or any nasal traumaAs corticosteroids may cause immunosuppression, patients should notify healthcare providers if they experience any symptoms of tuberculosis, viral, bacterial, fungal or parasitic infections or ocular herpes simplexDue to the potential reduction in growth velocity in children, patients must be monitored routinelyLimited data from postmarketing experience over decades of use in pregnant women have not identified any drug associated risks of miscarriage, birth defects, or other adverse maternal or fetal outcomesThere are no available data on presence of azelastine hydrochloride or fluticasone propionate in human milk, effects on breastfed infant, or on milk production; breastfed infants should be monitored for signs of milk rejection during combination treatment by lactating women; fluticasone propionate is present in rat milkOther corticosteroids have been detected in human milk; however, fluticasone propionate concentrations in plasma after intranasal therapeutic doses are low and therefore concentrations in human breast milk are likely to be correspondingly low; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for combination treatment and any potential adverse effects on breastfed infant from therapy or from underlying maternal conditionA: Generally acceptable.

The major route of elimination is the excretion of fluticasone propionate and its metabolites in the bile. Co-treatment with other CYP 3A4 inhibitors, including cobicistat-containing products is also expected to increase the risk of systemic side effects.

One actuation (0.14 g) delivers 137 micrograms azelastine hydrochloride (= 125 micrograms azelastine) and 50 micrograms fluticasone propionate.One actuation (0.14 g) delivers 0.014 mg benzalkonium chloride.Relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.For full therapeutic benefit regular usage is essential. Administer by intranasal route only.